Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 290

Sort by

Sort Order Select

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Low-Grade Inflammation in Hemophilia

Lynn M Knowles, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 1115.

https://doi.org/10.1182/blood-2019-125127

Published: 2019

Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD

Blood (2019) 134 (Supplement_1): 4041.

https://doi.org/10.1182/blood-2019-127278

Published: 2019

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Vinita Dhir, BSc, Lara Zibdawi, Harminder K Paul, MSc, Osvaldo Espin-Garcia, PhD, Christine I Chen, MD, Michael Crump, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, John Kuruvilla, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD

Blood (2019) 134 (Supplement_1): 62.

https://doi.org/10.1182/blood-2019-131281

Published: 2019

Journal Articles

Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson

Francesco Tambaro, MD PhD, Dristhi Ragoonanan, Sajad Khazal, MD, Demetrios Petropoulos, MD, Priti Tewari, MD, Partow Kebriaei, MD, William G. Wierda, MD PhD, Mira A. Kohorst, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 4495.

https://doi.org/10.1182/blood-2019-132085

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD PhD, Chiara Salvetti, MD, Francesca Romana Mauro, MD, Daniela Pietrasanta, MD, Iolanda Donatella Vincelli, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, Marta Coscia, MD PhD

Blood (2019) 134 (Supplement_1): 3031.

https://doi.org/10.1182/blood-2019-125617

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Ralph V. Boccia, MD, Naomi V Dahl, PharmD, William E Strauss, MD

Blood (2019) 134 (Supplement_1): 2236.

https://doi.org/10.1182/blood-2019-126149

Published: 2019

Journal Articles

The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study

Wally R Smith, MD, Donna k McClish, PhD, Richard Lottenberg, MD, India Sisler, MD, Daniel Sop, BS,MS, Shirley Johnson, BA, LSW, Anthony Villella, MD, Darla K Liles, MD, Elizabeth Yang, MD PhD, Ian Chen, MD

Blood (2019) 134 (Supplement_1): 2309.

https://doi.org/10.1182/blood-2019-131201

Published: 2019

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

Deepa Bhojwani, MD, Bradley Peterson, MD, Agne Taraseviciute, MD PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Michael Sheard, PhD, Courtney Allem, Joey Trampush, PhD, Ravi Bansal, PhD

Blood (2019) 134 (Supplement_1): 1946.

https://doi.org/10.1182/blood-2019-127533

Published: 2019

Journal Articles

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

Wally R Smith, MD, Donna k McClish, PhD, Shirley Johnson, BA, LSW, Richard Lottenberg, MD, India Sisler, MD, Daniel Sop, BS,MS, Anthony Villella, MD, Darla K Liles, MD, Elizabeth Yang, MD PhD, Ian Chen, MD

Blood (2019) 134 (Supplement_1): 2168.

https://doi.org/10.1182/blood-2019-131266

Published: 2019

Journal Articles

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Sandhya R. Panch, MDMPH, Brent R. Logan, Jennifer A. Sees, MPH, Bipin N. Savani, MD, Nirali N. Shah, MD, Jack W. Hsu, MD, Michael A. Pulsipher, MD, Galen E. Switzer, PhD, Bronwen E. Shaw, MD PhD, David F. Stroncek, MD

Blood (2019) 134 (Supplement_1): 1962.

https://doi.org/10.1182/blood-2019-123492

Published: 2019

Journal Articles

Similar Hemostatic Responses to Hypovolemia in Hemorrhage and Lbnp Reveals a Hyperfibrinolytic Subset of Baboons

Maryanne Herzig, PhD, Morten Zaar, PhD, Chriselda Fedyk, Bijaya Kumar Parida, PhD, Carmen Hinojosa-Laborde, PhD, Robert E Shade, PhD, Heather F. Pidcoke, MD PhD, Victor A Convertion, PhD, Andrew P. Cap, MD PhD

Blood (2019) 134 (Supplement_1): 3633.

https://doi.org/10.1182/blood-2019-131792

Published: 2019

Journal Articles

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

Giovanni Marconi, Federico Ravaioli, MD, Giovanni Martinelli, MD, Elton Dajti, Maria Chiara Abbenante, MD, Chiara Sartor, MD, Luigina Vanessa Alemanni, MD, Jacopo Nanni, MD, Sarah Parisi, MD PhD, Giovanni Marasco, MD, Gianluca Cristiano, MD, Amanda Vestito, MD, Francesca Bonifazi, Stefania Paolini, MD PhD, Antonio Curti, MD PhD, Davide Festi, MD, Michele Cavo, Cristina Papayannidis, Antonio Colecchia, MD

Blood (2019) 134 (Supplement_1): 1343.

https://doi.org/10.1182/blood-2019-130632

Published: 2019

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

NARROW

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Low-Grade Inflammation in Hemophilia

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Similar Hemostatic Responses to Hypovolemia in Hemorrhage and Lbnp Reveals a Hyperfibrinolytic Subset of Baboons

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only